Edition:
India

Livzon Pharmaceutical Group Inc (1513.HK)

1513.HK on Hong Kong Stock

67.90HKD
16 Jan 2018
Change (% chg)

HK$1.35 (+2.03%)
Prev Close
HK$66.55
Open
HK$66.10
Day's High
HK$68.70
Day's Low
HK$66.10
Volume
827,984
Avg. Vol
514,598
52-wk High
HK$68.90
52-wk Low
HK$32.54

Select another date:

Fri, Jan 12 2018

REFILE-BRIEF-Livzon Pharmaceutical'ss Board Agrees Unit To Invest $30 Mln In Global Health Science Fund II

* SAYS BOARD AGREES UNIT TO INVEST $30 MILLION IN GLOBAL HEALTH SCIENCE FUND II, L.P. Source text in Chinese: http://bit.ly/2CVb0qK Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Livzon Pharmaceutical Group receives subsidy of 12.8 mln yuan

* Says it received subsidy of 12.8 million yuan for injection internationalization and development related projects

BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial

* Says Zhuhai-based biotechnology unit received drug clinical trial approval for drug named Recombinant Human anti-RANKL Monoclonal Antibody Solution for Injection

BRIEF-Livzon Pharmaceutical Co Announces Change In Shareholding Structure Of Livzon MABPharm

* CO & JOINCARE PHARMACEUTICAL INDUSTRY ENTERED FRAMEWORK AGREEMENT RELATING TO CAPITAL CONTRIBUTION TO LIVZON BIOLOGICS

BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial

* Says its unit received drug clinical trial approval for Recombinant Humanized anti-PD-1 Monoclonal Antibody for Injection

BRIEF-Livzon Pharmaceutical's net profits up in Q3, Jan-Sept

* Says Q3 net profit up 1,719.2 percent y/y at 3.7 billion yuan ($556.85 million), 9-month net profit up 590.7 percent y/y at 4.2 billion yuan

BRIEF-Livzon Pharmaceutical sees FY net profit attributable between RMB4.32 bln - RMB4.48 bln

* Sees FY net profit attributable between RMB4.32 billion - RMB4.48 billion Source text for Eikon: Further company coverage:

BRIEF-Livzon Pharmaceutical Group units receive approval for drug clinical trials

* Says its units received drug clinical trials approval for drug, Triptorelin Acetate Microspheres for Injection

BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial

* Says its unit received drug clinical trial approval for antineoplastic, Paclitaxel polymeric micelles for injection

BRIEF-Livzon Pharmaceutical Group says change of accounting policies

* Says it changes accounting policies regarding government subsidy, non-current assets, disposal groups and discontinued operations

Select another date: